Development of Transdiagnostic Single-session Treatment
NCT ID: NCT05784259
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
300 participants
INTERVENTIONAL
2023-10-01
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress?
* Will the transdiagnostic treatment program decrease transdiagnostic risk factors?
* Will the transdiagnostic treatment program decrease the measured risk factors equally?
* Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally?
* Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors?
* Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms?
* Have the participants been able to generalize the skills taught in the program(qualitative)?
* Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions.
The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
No interventions assigned to this group
Treatment group
Transdiagnostic single-session treatment
Transdiagnostic single-session treatment
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transdiagnostic single-session treatment
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptoms are mild to moderate in severity
Exclusion Criteria
* Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose
* Has a comorbid personality disorder
* Has a risk of suicide deemed other than low
* Has other severe psychological disorders outside the scope of primary care
* Is in a severely stressful social situation deemed incompatible with psychotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Norrbotten
UNKNOWN
Luleå Tekniska Universitet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Näsling
Lic. psychologist / Doctoral student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Näsling, Master
Role: PRINCIPAL_INVESTIGATOR
Luleå tekniska universitet/Region Norrbotten
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Region Norrbotten, Primary care
Luleå, Norrbotten County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
John Näsling
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
275863
Identifier Type: -
Identifier Source: org_study_id